RecruitingRecruiting
Molecular and Genetic Analysis of Lung Cancer
NCT03029325 · Massachusetts General Hospital
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
Investigators also investigate how genetic variants may affect cancer treatment, at various stages of disease development, in order to determine prognostic and predictive factors for survival.
Eligibility criteria
Inclusion Criteria:
* healthy controls: participants without evidence of any cancer
* cases: pathology proven primary lung cancer
Exclusion Criteria:
* younger than 18 years old
Study design
Enrollment target: 15000 participants
Age groups: adult, older_adult
Timeline
Starts: 1993-06
Estimated completion: 2026-09
Last updated: 2024-11-29
Primary outcomes
- • Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression (20 years)
Sponsor
Massachusetts General Hospital · other
With: National Cancer Institute (NCI)
Contacts & investigators
ContactDavid Christiani, MD · contact · dchris@hsph.harvard.edu · 617-726-9274
ContactAndrea Shafer, MPH · contact · ashafer@mgh.harvard.edu · 6177269274
InvestigatorDavid C Christiani, MD · principal_investigator, Harvard TH Chan School of Public Health
All locations (1)
Massachusetts General HospitalRecruiting
Boston, Massachusetts, United States